U.S. Stem Cell, Inc. (USRM)

U.S. Stem Cell Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	0.08	0.2	0.28	3.07	6.7
Revenue Growth (YoY)	-59.13%	-27.55%	-90.98%	-54.15%	21.38%
Cost of Revenue	0.02	0.05	0.06	1.34	2.11
Gross Profit	0.06	0.15	0.21	1.74	4.59
Selling, General & Admin	1.78	2.28	2.61	4.45	5.68
Research & Development	-	-	-	0	0.01
Operating Expenses	1.78	2.28	2.61	4.45	5.69
Operating Income	-1.72	-2.14	-2.4	-2.72	-1.1
Interest Expense	-0.69	-1	-0.49	-0.98	-1.44
Earnings From Equity Investments	-	-	-0.02	0.12	0.25
Other Non Operating Income (Expenses)	-	-	-	0.1	-
EBT Excluding Unusual Items	-2.41	-3.14	-2.91	-3.48	-2.29
Gain (Loss) on Sale of Assets	-	-	0.02	0.13	0.13
Legal Settlements	-	-	-	-0.7	-
Other Unusual Items	-0.45	-0.15	0	0.21	0.01
Pretax Income	-2.86	-3.29	-2.89	-3.84	-2.16
Net Income	-2.86	-3.29	-2.89	-3.84	-2.16
Net Income to Common	-2.86	-3.29	-2.89	-3.84	-2.16
Shares Outstanding (Basic)	592	461	429	398	366
Shares Outstanding (Diluted)	592	461	429	398	366
Shares Change (YoY)	28.38%	7.34%	7.85%	8.86%	18.32%
EPS (Basic)	-0.00	-0.01	-0.01	-0.01	-0.01
EPS (Diluted)	-0.00	-0.01	-0.01	-0.01	-0.01
Free Cash Flow	-0.3	-1.06	-0.48	-1.21	0.6
Free Cash Flow Per Share	-0.00	-0.00	-0.00	-0.00	0.00
Gross Margin	71.03%	74.08%	76.86%	56.54%	68.50%
Operating Margin	-2096.90%	-1063.94%	-866.24%	-88.47%	-16.38%
Profit Margin	-3483.21%	-1637.58%	-1043.17%	-124.84%	-32.24%
Free Cash Flow Margin	-371.55%	-527.00%	-172.83%	-39.42%	8.99%
EBITDA	-	-	-2.16	-2.48	-0.89
EBITDA Margin	-	-	-	-80.57%	-13.29%
D&A For EBITDA	-	-	0.24	0.24	0.21
EBIT	-1.72	-2.14	-2.4	-2.72	-1.1
EBIT Margin	-	-	-	-88.47%	-16.38%
Revenue as Reported	0.08	0.2	0.28	3.07	6.7

Updated Apr 14, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.